Previous 10 | Next 10 |
Noteworthy events during the week of October 13 - 19 for healthcare investors. More news on: Flexion Therapeutics, Inc., Johnson & Johnson, ArQule, Inc., Healthcare stocks news, , Read more ...
PALO ALTO, Calif. , Oct. 11, 2019 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD) will host an R&D Day in San Francisco to highlight significant progress in the development of its lead therapeutic candidate KSI-301. The R&D event, including a live video stream, will be held o...
PALO ALTO, Calif. , Oct. 10, 2019 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), a clinical stage biopharmaceutical company specializing in novel therapeutics to treat chronic, high-prevalence retinal diseases, announced that the first patients have been treated in the DAZZLE pivotal...
It's almost time for the American Academy of Opthalmology's (AAO) annual meeting again, and this year's event will contain some high-stakes presentations. This year, all three of these biopharmaceutical companies will present clinical trial results that could send their stock prices soaring -- o...
PALO ALTO, Calif. , Oct. 7, 2019 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), a clinical stage biopharmaceutical company specializing in novel therapeutics to treat chronic, high-prevalence retinal diseases, today announced that Charles C. Wykoff , M.D., Ph.D., will present first-...
Over the past three months, the Nasdaq Biotechnology index has tumbled around 9.5% and industrywide worries have pressured share prices of some companies that didn't deserve a market beatdown. Axsome Therapeutics (NASDAQ: AXSM) , BridgeBio Pharma (NASDAQ: BBIO) , and Kodiak Sciences (...
The biotech industry's summer doldrums are finally over and a handful of stocks recently posted some big gains for different reasons. Should we expect more gains ahead from these drugmakers or have they reached a peak? Let's look at what drove these biotech stocks higher during the week ended...
PALO ALTO, Calif. , Sept. 15, 2019 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), a clinical-stage biopharmaceutical company specializing in novel therapeutics to treat chronic, high-prevalence retinal diseases, today announced emerging durability data in patients with wet age-r...
PALO ALTO, Calif. , Sept. 12, 2019 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), a clinical-stage biopharmaceutical company specializing in novel therapeutics to treat chronic, high-prevalence retinal diseases, today announced that updated data from the clinical development program ...
PALO ALTO, Calif. , Sept. 6, 2019 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), a clinical-stage biopharmaceutical company specializing in novel therapeutics to treat chronic, high-prevalence retinal diseases, today announced that management will participate in the Morgan Stanl...
News, Short Squeeze, Breakout and More Instantly...
Kodiak Sciences Announces Recent Business Highlights and First Quarter 2024 Financial Results PR Newswire PALO ALTO, Calif. , May 15, 2024 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), today reported business highlights and financial results for the qu...
Kodiak Sciences Announces Treatment of First Patients in Phase 3 GLOW2 Study of Tarcocimab Tedromer in Diabetic Retinopathy PR Newswire PALO ALTO, Calif. , May 13, 2024 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), a biopharmaceutical company committed to r...
Kodiak Sciences Data at ARVO 2024 Highlight Depth of Early and Late-Phase Retina Pipeline including Advancements with High Drug-Antibody-Ratio Therapeutics Built on Kodiak's Antibody Biopolymer Conjugate (ABC) Platform PR Newswire Tarcocimab clinical and non-clinical data high...